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Congenital dyserythropoietic anemias (CDAs) constitute a rare group of inherited red-blood-cell disorders associated
with dysplastic changes in late erythroid precursors. CDA type I (CDAI [MIM 224120], gene symbol CDAN1) is
characterized by erythroid pathological features such as internuclear chromatin bridges, spongy heterochromatin,
and invagination of the nuclear membrane, carrying cytoplasmic organelles into the nucleus. A cluster of 45 highly
inbred Israeli Bedouin with CDAI enabled the mapping of the CDAN1 disease gene to a 2-Mb interval, now refined
to 1.2 Mb, containing 15 candidate genes on human chromosome 15q15 (Tamary et al. 1998). After the char-
acterization and exclusion of 13 of these genes, we identified the CDAN1 gene through 12 different mutations in
9 families with CDAI. This 28-exon gene, which is transcribed ubiquitously into 4738 nt mRNA, was reconstructed
on the basis of gene prediction and homology searches. It encodes codanin-1, a putative o-glycosylated protein of
1,226 amino acids, with no obvious transmembrane domains. Codanin-1 has a 150-residue amino-terminal domain
with sequence similarity to collagens and two shorter segments that show weak similarities to the microtubule-
associated proteins, MAP1B (neuraxin) and synapsin. These findings, and the cellular phenotype, suggest that
codanin-1 may be involved in nuclear envelope integrity, conceivably related to microtubule attachments. The
specific mechanisms by which codanin-1 underlies normal erythropoiesis remain to be elucidated.
Congenital dyserythropoietic anemias (CDAs), a group
of inherited disorders associatedwithmorphological and
functional abnormalities of erythropoiesis, have been
classified into three types (I–III), with some patients still
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unassigned (Wickramasinghe 1997; Delaunay and Io-
lascon 1999). The autosomal recessive CDA type II
(CDAII [MIM 224100]), with more than 250 cases de-
scribed to date (Iolascon et al. 2001), is the most com-
mon form. The disease gene maps to 20q11.2 in most
studied families (Gasparini et al. 1997). The least com-
mon of the CDAs, the autosomal dominant CDA type
III (CDAIII [MIM 105600]), was localized to chromo-
some 15q22 upon linkage analysis of a large Swedish
family (Lind et al. 1995).
CDA type I (CDAI [MIM 224120]) is an autosomal
recessive disease. Patients with CDAI present with mod-
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Figure 1 Physical map and genomic organization of the CDAN1 locus. a, Relative positions of landmark microsatellite markers are
indicated in the CDAI candidate interval defined by markers D15S779 and D15S778. The CDA1 interval is indicated by green and brown
arrows. An informative SNP (pink) within the newly defined transcript LOC146050 enabled us to restrict the linkage interval. The genes and
transcripts identified are boxed: known genes in green, unknown transcripts in blue, inferred genes in purple, CDAN1 in red. The expression
patterns of these genes were tested by RT-PCR on RNA from erythroid precursor cells (Pope et al. 2000) and are marked by a plus sign ()
or a minus sign () in the Express lane. Resequenced genes are marked by a plus sign () or a minus sign () in the Reseq lane. b, Expanded
view of the 15-kb segment showing the genomic organization of CDAN1 and of two alternative transcripts isolated and sequenced from erythroid
and fibroblast cells. Coding and noncoding exons are depicted as filled and open boxes, respectively. Red and blue exons are based on two
partial transcripts, DKFZp434G2127 and BI855138, respectively. Green and pink exons are based on gene prediction and RT-PCR, respectively.
The lengths of the corresponding transcripts and inferred proteins are indicated to the right.
erate-to-severe macrocytic anemia. Bone marrow aspi-
rates reveal binuclear intermediate- and late-erythroid
precursors as well as internuclear chromatin bridges. Ul-
trastructural erythroid features include spongy hetero-
chromatin and invagination of the nuclear membrane,
carrying cytoplasm and cytoplasmic organelles into the
nucleus. Dysmorphic features, mainly syndactyly and the
absence or hypoplasia of phalanges and nails, have also
been observed in several patients (Wickramasinghe
1997). Arrest of DNA synthesis (Wickramasinghe 1997)
and apoptotic features in erythroid precursors have been
described (Tamary et al. 1996). Interferon a2 was in-
cidentally found to ameliorate the anemia and to par-
tially reverse the morphological abnormalities of the
erythroid precursors by an unknown mechanism (Lav-
abre-Bertrand et al. 1995; Wickramasinghe et al. 1997;
Parez et al. 2000). A cluster of 45 Israeli Bedouin with
CDAI enabled mapping of the disease gene to a region
between markers D15S779 and D15S778 (Tamary et al.
1998). All patients showed a similar clinical picture, and
in all the subjects, the diagnosis was confirmed by bone
marrow electron microscopy. DNA was extracted from
whole blood, and RNA was extracted from the diag-
nostic bone marrow aspiration. All studies were ap-
proved by the institutional review board of Rabin Med-
ical Center. Using new polymorphic markers from
genomic clones (AC019011, AC018924) and an infor-
mative SNP within the defined transcript for the putative
transcription factor LOC146050, we further refined the
critical CDAI interval to 1.2 Mb (fig. 1a).
In an attempt to identify the underlying mutations,
we proceeded with systematic in silico analyses through
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Table 1
CODANIN-I Mutations in Patients with CDAI
ID, Family Origin,
Genotype, and Exona
Nucleotide
Positionb Amino Acid Change Frequency Detection Methodc
I, Israeli Bedouin, H:
24 3238CrT ArgrTrp (R1040W) 3/376 NcoI
II, French Polynesian, H:
26 3503CrT ProrLeu (P1129L) 0/142 AciI
III, European, H:
12 1910ArG AsnrSer (N598S) 0/196 DdeI
IV, European, CH:
14 2129CrT ProrLeu (P671L) 1/196 MspI
19 2716TrA PherIle (F866I) 0/170 MALDITOF
V, European, CH:
14 2158CrT Argrstop (R680X) 0/200 BtsI
14 2254CrT ArgrTrp (R712W) 1/164 BsrI
VI, European, CH:
23 3106CrT Argrstop (R996X) 0/196 TaqI
24 3242ArT AsprVal (D1041V) 0/180 MALDITOF
VII, European, CH:
14 2206GrA GlurLys (E696K) 0/160 MALDITOF
VIII, European, CH:
24 3221CrA SerrPhe (S1034F) 0/180 StyI
IX, Arab, CH:
19 2719GrA ValrMet (V867M) 1/180 NlaIII
NOTE.—A total of 184 chromosomes from healthy nonrelated Bedouin individuals were analyzed
as controls for the Bedouin mutation. For each of the additional mutations, close to 200 chromosomes
from unrelated control individuals were analyzed. Three carriers, each for one mutation, were found.
This is in accordance with the estimated frequency of CDAI heterozygotes in the Europeanpopulation.
a ID I included five families; all other IDs included one family each. H p homozygote; CH p
compound heterozygote.
b Nucleotide position in CODANIN-1 cDNA accession number AF525398.
c The mutation abolishes () or creates () a restriction site.
gene prediction and homology searches of the critical
CDAI interval and found 17 transcripts or putative
genes. Fifteen genes prevailed as potential candidates,
based on their expression as determined by RT-PCR
in erythroid cells grown in liquid culture (Pope et al.
2000), including two redefined and two newly char-
acterized transcripts, namely UBR1 (GenBank acces-
sion number AF525401), TTBK (GenBank accession
number AF525400), FLJ008 (GenBank accession
number AF525397) and LOC146050 (GenBank ac-
cession number AF525399). The remaining two genes,
Calpain3 (CAPN3) and TGM7, were not considered,
because they are not expressed in erythroid cells. The
predicted exons were amplified from genomic DNA or
from mRNA of erythroid precursors of one Bedouin
patient with CDAI and of his healthy brother. Thesewere
subjected to sequence verification andmutation detection.
Such systematic and comprehensive PCR and sequencing
analyses were carried out for all coding regions of 14 of
the 15 candidate genes (excluding KIAA1300, fig. 1a). All
PCR reactions were performed according to standard pro-
cedures, and the products were subsequently sequenced
using dye terminators of Big-Dyes kits on an ABI 3100
sequencer (Perkin-Elmer/Applied Biosystems). Sequence
comparisons were performed using the STADENpackage
(Bonfield et al. 1995) and Sequencher software (gene
codes cooperation).
In the first 13 genes tested, no segregating mutation
was identified; however, we eventually identified a ho-
mozygous mutation in the Bedouin patient in the four-
teenth gene scrutinized (table 1). This gene was recon-
structed on the basis of prediction programs and ho-
mology searches using two partial transcripts and two
EST sequences (fig. 1b). The gene, thus identified as
CDAN1, has 28 exons spanning 15 kb of genomic DNA
(fig. 1b). It encompasses a putative 4,738-nucleotide
mRNA encoding a protein of 1,226 amino acids, which
we propose to name Codanin-1, for CDA type I. Sub-
sequently, 11 additional mutations in eight other patient
groups with CDAI were identified in this gene (table 1).
A single homozygous CrT substitution in exon 24,
converting arginine to tryptophan at codon 1040 and
creating an NcoI restriction site, was found in all 45
analyzed Bedouin patients with CDAI (fig. 2C). One of
184 Israeli Arab and 2 of 192 independent Bedouin con-
trol chromosomes were found to be carriers of this mu-
tation (table 1). Subsequently, two other patients with
CDAI from two unrelated families were found to be
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Figure 2 The mutation in a Bedouin family. A, Pedigree of a
Bedouin family, showing the segregation of the founder chromosome
with the disease. B, Sequence chromatogram from a wild-type (WT)
and diseased (M) genotype showing a CrT substitution in exon 25,
converting arginine to tryptophan at codon 863. C, Segregation of the
Bedouin mutation, as assayed by NcoI restriction. A 412-bp PCR
product is generated between the F andR primers. Themutation results
in a gain of restriction site and, therefore, the restriction digest pro-
duced fragments of 175 and 237 bp, instead of the 412-bp band ob-
served in healthy individuals.
homozygous for two additional CDAN1 missense mu-
tations: a prolinerleucine substitution at codon 1129,
found in a French Polynesian patient, and an aspara-
ginerserine substitution at codon 598, present in three
affected brothers from a family of French origin (table
1). It is noteworthy that the three sibs also exhibit
sensorineural deafness and lack of motile sperm cells.
These symptoms can be accounted for by a large 70-kb
deletion 1 Mb distal to the CDAN1 gene (N. Avidan,
H. Tamary, O. Dgany, D. Cattan, A. Pariente, M. Thul-
liez, N. Borot, L. Moati, A. Barthelme, L. Shalmon, T.
Krasnov, E. Ben-Asher, T. Olender, M. Khen, I. Yaniv,
R. Zaizov, H. Shalev, J. Delaunay, M. Fellous, D. Lancet,
and J. S. Beckmann, unpublished data). Hence, discovery
of the ArG substitution in exon 12 indicates that these
brothers carry, in addition to the 70-kb deletion, a mis-
sense mutation in CDAN1 responsible for the CDAI
phenotype. It is surprising to find tightly linked inde-
pendent mutations on the same haplotype. However,
cases of contiguous gene syndromes have been reported
(Bitner-Glindzicz et al. 2000; Parvari et al. 2001; Shan-
ske et al. 2001); given the growing number of mapped
genetic disorders, such cases may be frequent enough to
be encountered.
Three sporadic European patients with CDAI were
found to be compound heterozygotes for CDAN1 mu-
tations. One patient has two distinct missensemutations,
whereas the other two have one null and one missense
mutation each (table 1). Segregation analysis of each
mutation in respective families and genotyping of con-
trol chromosomes was done by restriction fragment
analysis (NEBiolabs) or by mass spectrometry SNP scor-
ing (Sauer et al. 2002) (primers available upon request).
Segregation analysis demonstrated that all patients in-
herited one mutation from each parent, thus confirming
that the patients are true compound heterozygotes. In
addition, two patients of European descent and one of
Arab descent were shown to carry one distinct missense
mutation each (table 1). The unidentified mutations may
be located in the promoter or introns of CDAN1 or in
some as-yet-unidentified exons. It is noteworthy that one
additional patient (diagnosed by A.I.), who presented
the clinical characteristics of CDAI, was found to be
merely a compound heterozygote for two synonymous
nucleotide changes (data not shown). For this patient
with CDAI, pathogenic mutations remain to be identi-
fied either in CDAN1 or in a second locus involved in
the etiology of this disease. In any event, our data imply
a considerable molecular homogeneity for CDAI.
In total, 12 different mutations in nine families with
CDAI were identified: 4 in exon 14, 3 in exon 24, 2 in
exon 19, and 1 each in exons 12, 23, and 26. The mu-
tation-clustering pattern suggests either that these exons
are more prone to mutation or that they encode essential
functional domains (table 1). Furthermore, although
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Figure 3 Northern blot analysis. Panels A and B show CDAN1
and b-actin mRNA exposed for 1 week and overnight, respectively.
The membrane was purchased from Clontech and was hybridized ac-
cording to the manufacturer’s instructions. The membrane was first
probed with codanin-1 (exons 26–28 [fig. 1]) and subsequently re-
probed with b-actin cDNA as an internal control.
nonsense mutations were found in two compound het-
erozygotes, no homozygote for null-type mutations has
been identified. This suggests that codanin-1 may have
a unique and essential function, with very little redun-
dancy. Future knockout studies and further screening of
patients with CDAI should indicate whether the lack of
this protein is lethal. In addition, the diversity of the
severity of the disease among homozygous Bedouin pa-
tients with CDAI suggests that modifier genes may mod-
ulate the phenotype. Hence, at this stage, it is impossible
to establish precise phenotype-genotype correlation.
Northern blot analysis was performed with a cDNA
probe for exons 26–28 on RNA from eight different
human tissues (Clontech). All tissues expressed the same
4.7-kb band (fig. 3A), suggesting that the gene is ubiq-
uitously expressed and that the inferred mRNA is close
to full length. A 369-bp shorter, alternatively spliced
variant was found upon RT-PCR (data not shown) to
be coexpressed in fibroblast cell line cultures from both
patients with CDAI and healthy control individuals but
not in erythroid cells. It is generated by in-exon splicing
of exons 11–14 (fig. 1b), which preserves the original
reading frame. This mRNA isoform encodes a putative
protein of 1,103 amino acids. This major CDAN1
mRNA appears to be expressed at a level at least tenfold
lower than b-actin control as evidenced by their relative
exposure times (fig. 3B). This observation is in agree-
ment with the results of expression array experiments
(data not shown) and the low number of CDAN1 ESTs
present in the databases.
BLAST homology searches (Altschul et al. 1990)
against several genomic sequence databases showed no
obvious human codanin-1 paralog but revealed two pu-
tative orthologs: one in the mouse syntenic region (84%
identity) and one in Fugu rubripes (44% identity) (fig. 4).
We also identified a putative ortholog in Drosophila me-
lanogaster (GenBank accession number AF487678S2),
which shares 23% identity with codanin-1. This protein,
vanaso, has been proposed to be involved in the fly’s
olfactory behavior and is unlikely to be a functional
CDAN1 ortholog. Codanin-1 has no clear intracellular
location-specific domains, such as a transmembrane or
a signal peptide segments; it contains, however, numer-
ous o-glycosylation consensus sites. In addition, the
amino-terminal domain shares a significant homology
with fibrillar collagens as revealed by FASTA (Pearson
and Lipman 1988) (fig. 4). A multiple alignment was
performed using the CLUSTALX program with the de-
fault parameters (Higgins et al. 1996). Further domain
analysis was performed by BLOCKS (Henikoff et al.
2000), defining 13 interspecies sequence conservation
regions (fig. 4). Subsequently, these BLOCKs were com-
pared with all BLOCK database motifs, using the Local
Alignment of Multiple Alignment method (Pietrokovski
1996). Similarities to two domains of the microtubule-
associated protein MAP1B (Noble et al. 1989) (fig. 4,
green shaded blocks C and E) and to two domains of
fibrillar collagen triple-helix repeats (Silver et al. 2002)
(fig. 4, pink shaded blocks A and G) were unveiled.
Using CYRCA, more remote, indirect similarities were
further detected between the triple-helix repeats blocks
and synapsins blocks, a protein family known to be in-
volved in binding diverse substrates including actin,
spectrin, and microtubules (Angers et al. 2002). CYRCA
is a method developed to identify blocks of potentially
similar function and structure appearing in different con-
texts (Kunin et al. 2001). On the basis of the disease
phenotype, which includes spongy heterochromatin and
invagination of the nuclear membrane, and the protein
similarity results, we speculate that codanin-1 might be
involved in nuclear membrane integrity by connecting
the nuclear membrane and microtubules (Dreger et al.
2001; Lippincott-Schwartz 2002).
Further analysis of codanin-1, using antibodies and
animal models, should help to unravel the mechanism
by which this protein ensures nuclear integrity during
erythropoiesis, to clarify the pathogenesis of the disease,
and possibly to facilitate the development of novel strat-
egies for its management. Furthermore, identification of
the gene involved in CDAI may facilitate the cloning of
the genes involved in other types of CDA.
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